Lipid-lowering therapy for the primary prevention of coronary heart disease

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Primary prevention of coronary heart disease is a critical component of reducing the societal burden of atherosclerosis. In the current editorial, data from trials of lipid modification as primary-prevention strategies will be reviewed. Trials of the HMG-CoA reductase inhibitors have demonstrated significant benefits on coronary morbidity in patients without heart disease, and the implications of these studies on current guidelines will be discussed with a focus on the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

Original languageEnglish (US)
Pages (from-to)2078-2082
Number of pages5
JournalJournal of the American College of Cardiology
Issue number7
StatePublished - Jun 1999

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Lipid-lowering therapy for the primary prevention of coronary heart disease'. Together they form a unique fingerprint.

Cite this